Tandutinib
Tandutinib Basic information
- Product Name:
- Tandutinib
- Synonyms:
-
- Tandutinib
- 1-Piperazinecarboxamide, 4-(6-methoxy-7-(3-(1-piperidinyl)propoxy)-4-quinazolinyl)-N-(4-(1-methylethoxy)phenyl)-
- 4-(6-Methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl)piperazine-1-carboxylic acid (4-isopropoxyphenyl)amide
- Unii-E1io3icj9a
- Tandutinib(CT 53518)
- Tandutinib (MLN518)
- CT53518; MLN518
- Tandutinib(TINIBS)
- CAS:
- 387867-13-2
- MF:
- C31H42N6O4
- MW:
- 562.7
- Product Categories:
-
- Inhibitors
- ZUBRIN
- API
- Intermediates & Fine Chemicals
- Pharmaceuticals
- Tyrosine Kinase Inhibitors
- Mol File:
- 387867-13-2.mol
Tandutinib Chemical Properties
- Melting point:
- 177-178°C
- Boiling point:
- 769.5±60.0 °C(Predicted)
- Density
- 1.213±0.06 g/cm3(Predicted)
- storage temp.
- Sealed in dry,Store in freezer, under -20°C
- solubility
- Chloroform (Slightly), Methanol (Slightly)
- pka
- 13.39±0.70(Predicted)
- form
- Solid
- color
- White to Off-White
- CAS DataBase Reference
- 387867-13-2(CAS DataBase Reference)
Tandutinib Usage And Synthesis
Description
Tandutinib is a potent antagonist of platelet-
Chemical Properties
White Solid
Uses
An oral, small-molecule inhibitor of FLT3 for the treatment of AML (acute myelogenous leukemia) and other cancer indications. The drug exhibited limited activity as a single agent in phase I and II clinical trials in patients with AML and myelody
Uses
antipsoratic
Uses
An oral, small-molecule inhibitor of FLT3 for the treatment of AML (acute myelogenous leukemia) clinical trials in patients with AML and myelodysplastic syndrome, but displayed promising antileukemic activity (90% complete remissions) in a phase I/II trial in patients with newly diagnosed AML w hen administered in combination with cytarabine and daunorubicin.
Definition
ChEBI: An N-arylpiperazine that is piperazine in which the hydrogen attached to the nitrogen at position 1 is replaced by a 6-methoxy-7-[3-(piperidin-1-yl)propoxy]quinazolin-4-yl group, while the hydrogen attached to the nitrogen at position 4 s replaced by a (p-isopropoxyphenyl)aminocarbonyl group. Tandutinib is an inhibitor of tyrosine kinases FLT3, PDGFR and KIT.
target
c-Kit
References
[1] kelly lm1, yu jc, boulton cl, apatira m, li j, sullivan cm, williams i, amaral sm, curley dp, duclos n, neuberg d, scarborough rm, pandey a, hollenbach s, abe k, lokker na, gilliland dg, giese na. ct53518, a novel selective flt3 antagonist for the treatment of acute myelogenous leukemia (aml). cancer cell. 2002 jun;1(5):421-32.
TandutinibSupplier
- Tel
- 021-20986266 18019349802
- 814527417@qq.com
- Tel
- sales@boylechem.com
- Tel
- 010-82848833 400-666-7788
- jkinfo@jkchemical.com
- Tel
- +86-21-20908456
- sales@BioChemBest.com
- Tel
- 1-(800)-881-8210
- inquiries@lgmpharma.com